The European Brain Council Value of Treatment studies in depression and autism

Abstract

The European Brain Council (EBC) has partnered with European Psychiatry to present a collection of studies on the value of treatment for depression and autism. The studies focus on identifying treatment gaps, evaluating outcomes and costs, and making policy recommendations. The research reveals significant gaps in the care pathways for patients with major depressive disorder (MDD) and autism spectrum disorders (ASD) in Europe. These gaps include underdiagnosis, lack of treatment, delays in treatment, and inadequate follow-up care. The studies also highlight the impact of the COVID-19 pandemic on treatment rates and access to care for MDD. Additionally, the economic analysis shows that reducing treatment gaps in MDD can lead to long-term cost-efficiency. For ASD, the studies demonstrate gaps in care pathways, including delays in diagnostic appointments, lack of support for carers, and insufficient screening for comorbid epilepsy. The research also examines the economic outcomes of early intervention for autistic children, showing improvements in symptoms and cost-saving in terms of informal care. Overall, these studies provide valuable insights into the challenges and potential solutions for improving the treatment and care of individuals with depression and autism in Europe.